This proposal aims at improving the efficiency and specificity of gene delivery in prostate cancer (PC) by using an innovative system consisting of ultrasound contrast agents, viral vectors and ultrasound waves. Additionally, this proposal aims at improving the response of prostate cancer to radiation therapy. Despite the progress of modern radiation techniques in largely improving the prognosis of patients with prostate adenocarcinoma, the maximum benefit that can be achieved with conventional radiation therapy has probably been reached. The impact of this proposal lies in the fact that a gene such as p130 significantly increases the percentage of apoptotic cells after 3- irradiation potentially improving the treatment of prostate cancer. Additionally, ultrasound contrast agents offer the advantage of targeted gene release, thereby improving its specificity. The impact of microbubbles on gene therapy is to protect the viral vectors from rapid degradation by the immune system thus allowing for intravenous injection rather than direct target organ injection. Ultrasound contrast agents (microbubbles) may be designed to serve as safe vehicles to encapsulate and deliver genetic materials. The gas filled microspheres effectively lower the energy threshold for cavitation. This allows diagnostic transducers operating within the energy levels mandated by the FDA to be used for drug/gene delivery. In the sonification zone the microbubbles undergo cavitation, destroying the bubbles and releasing their contents. Cavitation also creates small shockwaves that increase cell permeability. This has been shown to increase transcapillary passage of macromolecules or nanoshperes codelivered by the microbubbles in experimental animals. This proposal aims at improving the outcome of radiation therapy in prostate cancer. The outcome of these studies will demonstrate whether targeted p130 gene delivery is an effective adjuvant treatment in the therapy of prostate adenocarcinoma and whether its use could be directed at decreasing treatment-related morbidity. The results of these experiments will be the basis for future patient clinical trials.

Public Health Relevance

This proposal aims at improving the efficiency and specificity of gene delivery in prostate cancer (PC) by using an innovative system consisting of ultrasound contrast agents, viral vectors and ultrasound waves. Additionally, this proposal aims at improving the response of prostate cancer to radiation therapy. Despite the progress of modern radiation techniques in largely improving the prognosis of patients with prostate adenocarcinoma, the maximum benefit that can be achieved with conventional radiation therapy has probably been reached. The impact of this proposal lies in the fact that a gene such as p130 significantly increases the percentage of apoptotic cells after 3- irradiation potentially improving the treatment of prostate cancer. Additionally, ultrasound contrast agents offer the advantage of targeted gene release, thereby improving its specificity. The impact of microbubbles on gene therapy is to protect the viral vectors from rapid degradation by the immune system thus allowing for intravenous injection rather than direct target organ injection. Additionally, viruses are non-specific. Ultrasound contrast agents (microbubbles) may be designed to serve as safe vehicles to encapsulate and deliver genetic materials. The gas filled microspheres effectively lower the energy threshold for cavitation. This allows diagnostic transducers operating within the energy levels mandated by the FDA to be used for drug/gene delivery. In the sonification zone the microbubbles undergo cavitation, destroying the bubbles and releasing their contents. Cavitation also creates small shockwaves that increase cell permeability. This has been shown to increase transcapillary passage of macromolecules or nanoshperes codelivered by the microbubbles in experimental animals. In conclusion, this proposal aims at improving the outcome of radiation therapy in prostate cancer. The outcome of these studies will demonstrate whether targeted p130 gene delivery is an effective adjuvant treatment in the therapy of prostate adenocarcinoma and whether its use could be directed at decreasing treatment-related morbidity. The results of these experiments will be the basis for future patient clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA131395-02
Application #
7759519
Study Section
Radiation Therapeutics and Biology Study Section (RTB)
Program Officer
Farahani, Keyvan
Project Start
2009-04-01
Project End
2013-03-31
Budget Start
2010-04-01
Budget End
2013-03-31
Support Year
2
Fiscal Year
2010
Total Cost
$154,000
Indirect Cost
Name
Marshall University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
036156615
City
Huntington
State
WV
Country
United States
Zip Code
25701
Wolf, M Allison; Claudio, Pier Paolo (2014) Benzyl isothiocyanate inhibits HNSCC cell migration and invasion, and sensitizes HNSCC cells to cisplatin. Nutr Cancer 66:285-94
Nande, Rounak; Greco, Adelaide; Gossman, Michael S et al. (2013) Microbubble-assisted p53, RB, and p130 gene transfer in combination with radiation therapy in prostate cancer. Curr Gene Ther 13:163-74
De Carlo, Flavia; Witte, Theodore R; Hardman, W Elaine et al. (2013) Omega-3 eicosapentaenoic acid decreases CD133 colon cancer stem-like cell marker expression while increasing sensitivity to chemotherapy. PLoS One 8:e69760
Aimola, Pierpaolo; Carmignani, Marco; Volpe, Anna Rita et al. (2012) Cadmium induces p53-dependent apoptosis in human prostate epithelial cells. PLoS One 7:e33647
Nande, Rounak; Di Benedetto, Altomare; Aimola, Pierpaolo et al. (2012) Targeting a newly established spontaneous feline fibrosarcoma cell line by gene transfer. PLoS One 7:e37743
Gossman, Michael S; Das, Indra J; Sharma, Subhash C et al. (2011) A novel phantom model for mouse tumor dose assessment under MV beams. Health Phys 101:746-53
Greco, Adelaide; Di Benedetto, Altomare; Howard, Candace M et al. (2010) Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol Ther 18:295-306